Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement

Details

Ressource 1Download: 17416415.pdf (267.74 [Ko])
State: Public
Version: Author's accepted manuscript
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_EDE42B00030B
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
Title
Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement
Journal
Leukemia Research
Author(s)
Knipp  S., Gattermann  N., Schapira  M., Kaferstein  H., Germing  U.
ISSN
0145-2126 (Print)
Publication state
Published
Issued date
11/2007
Volume
31
Number
11
Pages
1585-7
Language
english
Notes
Journal Article --- Old month value: Nov
Abstract
We report on a 42-year-old patient whose relapse of acute promyelocytic leukaemia (APL) included meningeal infiltration. Since he had previously experienced ATRA syndrome, he received arsenic trioxide (ATO) plus intrathecal therapy with cytarabine, prednisone, and methotrexate. We measured the concentration of arsenic in his cerebrospinal fluid (CSF). Arsenic showed a peak CSF concentration of 0.008mg/l (0.11mumol/l) and a nadir of 0.002mg/l (0.027mumol/l), both representing about 14% of blood levels. ATO thus crosses the blood-CSF-barrier when administered intravenously, but the concentration in CSF is probably not sufficient for treatment of meningeal leukemia.
Pubmed
Web of science
Create date
25/01/2008 15:27
Last modification date
20/08/2019 16:15
Usage data